Responses
Diabetes and endocrinology
Protocol
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
Compose a Response to This Article
Other responses
No responses have been published for this article.